Gedeon Richter
As of the edition of 20 October 2026, Gedeon Richter runs 12 drugs, 8 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 2 |
| Status not established | 2 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Estradiol | Ends 2032 (patent) | 6 |
| Ethinyl estradiol | none listed | 5 |
| Drospirenone | none listed | 5 |
| Relugolix | Ends 2033 (patent) | 3 |
| Cariprazine | Ends 2029 (patent) | 4 |
| Norethindrone acetate | none listed | 3 |
| Estetrol anhydrous | none listed | 2 |
| Norelgestromin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Gedeon Richter needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 3 trials led
- Bones, joints and muscles: 2 trials led
- Immune system: 1 trials led